Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 13
2003 9
2004 7
2005 18
2006 16
2007 14
2008 20
2009 21
2010 30
2011 33
2012 27
2013 28
2014 32
2015 34
2016 64
2017 35
2018 37
2019 37
2020 41
2021 33
2022 49
2023 33
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

545 results

Results by year

Filters applied: . Clear all
Page 1
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Fischer L, Jiang L, Dürig J, Schmidt C, Stilgenbauer S, Bouabdallah K, Solal-Celigny P, Scholz CW, Feugier P, de Wit M, Trappe RU, Hallek M, Graeven U, Hänel M, Hoffmann M, Delwail V, Macro M, Greiner J, Giagounidis AAN, Dargel B, Durot E, Foussard C, Silkenstedt E, Weigert O, Pott C, Klapper W, Hiddemann W, Unterhalt M, Hoster E, Ribrag V, Dreyling M. Fischer L, et al. Among authors: hallek m. Leukemia. 2024 Apr 27. doi: 10.1038/s41375-024-02254-2. Online ahead of print. Leukemia. 2024. PMID: 38678093
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kutsch N, Simon F, Goede V, Hoechstetter MA, Niemann CU, da Cunha-Bang C, Kater AP, Dubois J, Gregor M, Staber PB, Tausch E, Schneider C, Stilgenbauer S, Eichhorst B, Fischer K, Hallek MJ. Langerbeins P, et al. Among authors: hallek mj. Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564. Online ahead of print. Blood. 2024. PMID: 38620092
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Fürstenau M, Giza A, Weiss J, Kleinert F, Robrecht S, Franzen F, Stumpf J, Langerbeins P, Al-Sawaf O, Simon F, Fink AM, Schneider C, Tausch E, Schetelig J, Dreger P, Böttcher S, Fischer K, Kreuzer KA, Ritgen M, Schilhabel A, Brüggemann M, Stilgenbauer S, Eichhorst B, Hallek M, Cramer P. Fürstenau M, et al. Among authors: hallek m. Blood. 2024 Apr 15:blood.2023022730. doi: 10.1182/blood.2023022730. Online ahead of print. Blood. 2024. PMID: 38620072
Post-transplant-cyclophosphamide and short-term Everolimus as graft-versus-host-prophylaxis in patients with relapsed/refractory lymphoma and myeloma-Final results of the phase II OCTET-EVER trial.
Richardson T, Scheid C, Herling M, Frenzel LP, Herling C, Aguilar MRC, Theurich S, Hallek M, Holtick U. Richardson T, et al. Among authors: hallek m. Eur J Haematol. 2024 Apr 14. doi: 10.1111/ejh.14210. Online ahead of print. Eur J Haematol. 2024. PMID: 38616351
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Cramer P, von Tresckow J, Fink AM, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, Langerbeins P, Fischer K, Kreuzer KA, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M. Cramer P, et al. Among authors: hallek m. Am J Hematol. 2024 Apr 5. doi: 10.1002/ajh.27304. Online ahead of print. Am J Hematol. 2024. PMID: 38578022 No abstract available.
An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL.
Prinz LF, Riet T, Neureuther DF, Lennartz S, Chrobok D, Hübbe H, Uhl G, Riet N, Hofmann P, Hösel M, Simon AG, Tetenborg L, Segbers P, Shimono J, Gödel P, Balke-Want H, Flümann R, Knittel G, Reinhardt HC, Scheid C, Büttner R, Chapuy B, Ullrich RT, Hallek M, Chmielewski MM. Prinz LF, et al. Among authors: hallek m. Cell Rep Med. 2024 Feb 20;5(2):101421. doi: 10.1016/j.xcrm.2024.101421. Epub 2024 Feb 9. Cell Rep Med. 2024. PMID: 38340727 Free PMC article.
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Mellinghoff SC, Robrecht S, Sprute R, Mayer L, Weskamm LM, Dahlke C, Gruell H, Teipel F, Schlößer HA, Siepmann K, Thelen M, Fink AM, Fischer K, Klein F, Addo MM, Kolovou A, Cornely OA, Eichhorst B, Hallek M, Langerbeins P. Mellinghoff SC, et al. Among authors: hallek m. Eur J Haematol. 2024 May;112(5):788-793. doi: 10.1111/ejh.14170. Epub 2024 Feb 4. Eur J Haematol. 2024. PMID: 38311570
545 results